JP2019088329A5 - - Google Patents

Download PDF

Info

Publication number: JP2019088329A5
Authority: JP; Japan
Prior art keywords: modified; modified oligonucleotide; seq; compound; nucleobase
Prior art date: 2019-02-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2019030128A

Other languages

English (en)

Japanese (ja)

Other versions

JP2019088329A (ja

Filing date

2019-02-22

Publication date

2019-08-29

2019-02-22 Application filed filed Critical

2019-06-13 Publication of JP2019088329A publication Critical patent/JP2019088329A/ja

2019-08-29 Publication of JP2019088329A5 publication Critical patent/JP2019088329A5/ja

Status Pending legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 claims 16
108091034117 Oligonucleotide Proteins 0.000 claims 12
239000002777 nucleoside Substances 0.000 claims 9
125000003835 nucleoside group Chemical group 0.000 claims 7
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
102100020948 Growth hormone receptor Human genes 0.000 claims 6
108010068542 Somatotropin Receptors Proteins 0.000 claims 6
230000000295 complement effect Effects 0.000 claims 6
239000008194 pharmaceutical composition Substances 0.000 claims 6
108020004707 nucleic acids Proteins 0.000 claims 5
150000007523 nucleic acids Chemical class 0.000 claims 5
102000039446 nucleic acids Human genes 0.000 claims 5
206010000599 Acromegaly Diseases 0.000 claims 3
102000018997 Growth Hormone Human genes 0.000 claims 3
108010051696 Growth Hormone Proteins 0.000 claims 3
125000002619 bicyclic group Chemical group 0.000 claims 3
201000010099 disease Diseases 0.000 claims 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
239000000122 growth hormone Substances 0.000 claims 3
241000282412 Homo Species 0.000 claims 2
239000000203 mixture Substances 0.000 claims 2
150000003833 nucleoside derivatives Chemical class 0.000 claims 2
LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
230000002265 prevention Effects 0.000 claims 1
150000003839 salts Chemical class 0.000 claims 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1

JP2019030128A 2013-07-02 2019-02-22 成長ホルモン受容体のモジュレータ Pending JP2019088329A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361842302P	2013-07-02	2013-07-02
US61/842,302		2013-07-02

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2016524320A Division JP6487913B2 (ja)	2013-07-02	2014-07-01	成長ホルモン受容体のモジュレータ

Publications (2)

Publication Number	Publication Date
JP2019088329A JP2019088329A (ja)	2019-06-13
JP2019088329A5 true JP2019088329A5 (2)	2019-08-29

Family

ID=52144275

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2016524320A Expired - Fee Related JP6487913B2 (ja)	2013-07-02	2014-07-01	成長ホルモン受容体のモジュレータ
JP2019030128A Pending JP2019088329A (ja)	2013-07-02	2019-02-22	成長ホルモン受容体のモジュレータ

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
JP2016524320A Expired - Fee Related JP6487913B2 (ja)	2013-07-02	2014-07-01	成長ホルモン受容体のモジュレータ

Country Status (13)

Country	Link
US (4)	US20170073689A1 (2)
EP (2)	EP3017044B1 (2)
JP (2)	JP6487913B2 (2)
KR (1)	KR102236784B1 (2)
CN (1)	CN105452461B (2)
AU (2)	AU2014284398B2 (2)
BR (1)	BR112015033069A2 (2)
CA (1)	CA2917229A1 (2)
ES (1)	ES2787600T3 (2)
IL (2)	IL243093B (2)
MX (1)	MX375446B (2)
RU (1)	RU2700244C2 (2)
WO (1)	WO2015002971A2 (2)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2991656T3 (da)	2013-05-01	2020-03-23	Ionis Pharmaceuticals Inc	Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
CN106103717A (zh)	2014-03-19	2016-11-09	Ionis制药公司	用于调节共济失调蛋白2表达的组合物
WO2015143245A1 (en)	2014-03-19	2015-09-24	Isis Pharmaceuticals, Inc.	Methods for modulating ataxin 2 expression
CN110903337A (zh) *	2014-05-01	2020-03-24	Ionis制药公司	用于调节生长激素受体表达的组合物和方法
US20190002887A1 (en)	2015-12-31	2019-01-03	Ionis Pharmaceuticals, Inc.	Methods for reducing ataxin-2 expression
EP4035659A1 (en)	2016-11-29	2022-08-03	PureTech LYT, Inc.	Exosomes for delivery of therapeutic agents
WO2019233922A1 (en)	2018-06-05	2019-12-12	F. Hoffmann-La Roche Ag	Oligonucleotides for modulating atxn2 expression
SG11202012759XA (en)	2018-07-03	2021-01-28	Hoffmann La Roche	Oligonucleotides for modulating tau expression
BR112021000308A2 (pt)	2018-07-25	2021-04-13	Ionis Pharmaceuticals, Inc.	Compostos e métodos para redução da expressão de atxn2
TW202028222A (zh) *	2018-11-14	2020-08-01	美商Ionis製藥公司	Foxp3表現之調節劑
US11286485B2 (en)	2019-04-04	2022-03-29	Hoffmann-La Roche Inc.	Oligonucleotides for modulating ATXN2 expression
EP4048801A4 (en) *	2019-10-24	2023-11-22	Genevant Sciences Gmbh	Conjugates and methods for treating acromegaly
KR20260005258A (ko) *	2023-04-21	2026-01-09	세카나 파머씨티컬스 지엠비에이치 엔 씨오. 케이지	Nrp1 특이적 안티센스 올리고뉴클레오티드 및 질병 예방 및/또는 치료에 있어서의 그 용도

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2699808A (en)	1944-10-06	1955-01-18	Mark W Lowe	Apparatus for peeling tomatoes
US2699508A (en)	1951-12-21	1955-01-11	Selectronics Inc	Method of mounting and construction of mounting for low frequency piezoelectric crystals
US5118800A (en)	1983-12-20	1992-06-02	California Institute Of Technology	Oligonucleotides possessing a primary amino group in the terminal nucleotide
FR2567892B1 (fr)	1984-07-19	1989-02-17	Centre Nat Rech Scient	Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5185444A (en)	1985-03-15	1993-02-09	Anti-Gene Deveopment Group	Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5034506A (en)	1985-03-15	1991-07-23	Anti-Gene Development Group	Uncharged morpholino-based polymers having achiral intersubunit linkages
US5506337A (en)	1985-03-15	1996-04-09	Antivirals Inc.	Morpholino-subunit combinatorial library and method
US5166315A (en)	1989-12-20	1992-11-24	Anti-Gene Development Group	Sequence-specific binding polymers for duplex nucleic acids
US5591722A (en)	1989-09-15	1997-01-07	Southern Research Institute	2'-deoxy-4'-thioribonucleosides and their antiviral activity
ATE269870T1 (de)	1989-10-24	2004-07-15	Isis Pharmaceuticals Inc	2'-modifizierte oligonukleotide
US5646265A (en)	1990-01-11	1997-07-08	Isis Pharmceuticals, Inc.	Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5670633A (en)	1990-01-11	1997-09-23	Isis Pharmaceuticals, Inc.	Sugar modified oligonucleotides that detect and modulate gene expression
GB9009980D0 (en)	1990-05-03	1990-06-27	Amersham Int Plc	Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
ES2116977T3 (es)	1990-05-11	1998-08-01	Microprobe Corp	Soportes solidos para ensayos de hibridacion de acidos nucleicos y metodos para inmovilizar oligonucleotidos de modo covalente.
EP0538194B1 (de)	1991-10-17	1997-06-04	Novartis AG	Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5359044A (en)	1991-12-13	1994-10-25	Isis Pharmaceuticals	Cyclobutyl oligonucleotide surrogates
FR2687679B1 (fr)	1992-02-05	1994-10-28	Centre Nat Rech Scient	Oligothionucleotides.
EP0577558A2 (de)	1992-07-01	1994-01-05	Ciba-Geigy Ag	Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
EP0673559A1 (en)	1992-12-14	1995-09-27	Honeywell Inc.	Motor system with individually controlled redundant windings
AU6449394A (en)	1993-03-30	1994-10-24	Sterling Winthrop Inc.	Acyclic nucleoside analogs and oligonucleotide sequences containing them
US5446137B1 (en)	1993-12-09	1998-10-06	Behringwerke Ag	Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en)	1994-01-11	1996-05-21	Isis Pharmaceuticals, Inc.	Pyrrolidine-containing monomers and oligomers
US5627053A (en)	1994-03-29	1997-05-06	Ribozyme Pharmaceuticals, Inc.	2'deoxy-2'-alkylnucleotide containing nucleic acid
US5597909A (en)	1994-08-25	1997-01-28	Chiron Corporation	Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5656408A (en)	1996-04-29	1997-08-12	Xerox Corporation	Coated carrier particles
JP3756313B2 (ja)	1997-03-07	2006-03-15	武今西	新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en)	1997-03-07	2004-08-03	Takeshi Imanishi	Bicyclonucleoside and oligonucleotide analogue
US6794499B2 (en)	1997-09-12	2004-09-21	Exiqon A/S	Oligonucleotide analogues
AU9063398A (en)	1997-09-12	1999-04-05	Exiqon A/S	Oligonucleotide analogues
US6043352A (en)	1998-08-07	2000-03-28	Isis Pharmaceuticals, Inc.	2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
WO2000063364A2 (en)	1999-04-21	2000-10-26	American Home Products Corporation	Methods and compositions for inhibiting the function of polynucleotide sequences
EP1178999B1 (en)	1999-05-04	2007-03-14	Santaris Pharma A/S	L-ribo-lna analogues
US6525191B1 (en)	1999-05-11	2003-02-25	Kanda S. Ramasamy	Conformationally constrained L-nucleosides
US9029523B2 (en) *	2000-04-26	2015-05-12	Ceres, Inc.	Promoter, promoter control elements, and combinations, and uses thereof
US8877916B2 (en) *	2000-04-26	2014-11-04	Ceres, Inc.	Promoter, promoter control elements, and combinations, and uses thereof
WO2001023616A2 (en) *	1999-09-29	2001-04-05	Genetic Vectors, Inc.	Method of identifying pathogenic cryptococci
US20050112118A1 (en) *	1999-12-02	2005-05-26	Myriad Genetics, Incorporated	Compositions and methods for treating inflammatory disorders
ES2261270T3 (es)	1999-12-30	2006-11-16	K.U. LEUVEN RESEARCH & DEVELOPMENT	Acidos nucleicos que contienen ciclohexeno.
AU2001250572A1 (en) *	2000-04-07	2001-10-23	Epigenomics Ag	Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
JP2005504020A (ja)	2001-07-03	2005-02-10	アイシス・ファーマシューティカルス・インコーポレーテッド	ヌクレアーゼ耐性キメラオリゴヌクレオチド
AU2003273336A1 (en) *	2002-09-18	2004-04-08	Isis Pharmaceuticals, Inc.	Efficient reduction of target rna's by single- and double-stranded oligomeric compounds
US8604183B2 (en)	2002-11-05	2013-12-10	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
CA2504694C (en)	2002-11-05	2013-10-01	Isis Pharmaceuticals, Inc.	Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US7250496B2 (en) *	2002-11-14	2007-07-31	Rosetta Genomics Ltd.	Bioinformatically detectable group of novel regulatory genes and uses thereof
US7314750B2 (en) *	2002-11-20	2008-01-01	Affymetrix, Inc.	Addressable oligonucleotide array of the rat genome
US6673661B1 (en)	2002-12-20	2004-01-06	Taiwan Semiconductor Manufacturing Co., Ltd.	Self-aligned method for forming dual gate thin film transistor (TFT) device
US7846906B2 (en)	2003-02-28	2010-12-07	Isis Pharmaceuticals, Inc.	Modulation of growth hormone receptor expression and insulin-like growth factor expression
US7803781B2 (en) *	2003-02-28	2010-09-28	Isis Pharmaceuticals, Inc.	Modulation of growth hormone receptor expression and insulin-like growth factor expression
WO2004106356A1 (en)	2003-05-27	2004-12-09	Syddansk Universitet	Functionalized nucleotide derivatives
EP1661905B9 (en)	2003-08-28	2012-12-19	IMANISHI, Takeshi	Novel artificial nucleic acids of n-o bond crosslinkage type
WO2005027962A1 (en)	2003-09-18	2005-03-31	Isis Pharmaceuticals, Inc.	4’-thionucleosides and oligomeric compounds
AU2005252663B2 (en)	2004-06-03	2011-07-07	Isis Pharmaceuticals, Inc.	Double strand compositions comprising differentially modified strands for use in gene modulation
US20080261905A1 (en)	2004-11-08	2008-10-23	K.U. Leuven Research And Development	Modified Nucleosides for Rna Interference
WO2007035771A2 (en) *	2005-09-19	2007-03-29	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Modulation of glucagon receptor expression
BRPI0616370A2 (pt) *	2005-09-19	2011-06-14	Johnson & Johnson Pharmaceutical Res & Dev L L C	modulaÇço da expressço de receptor de glucocorticàide
JP5342881B2 (ja)	2006-01-27	2013-11-13	アイシスファーマシューティカルズ，インコーポレーテッド	６−修飾された二環式核酸類似体
US8178503B2 (en) *	2006-03-03	2012-05-15	International Business Machines Corporation	Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
AU2007249349B2 (en)	2006-05-11	2012-03-08	Isis Pharmaceuticals, Inc.	5'-Modified bicyclic nucleic acid analogs
JP2010510807A (ja) *	2006-11-27	2010-04-08	アイシスファーマシューティカルズ，インコーポレーテッド	高コレステロール血症を治療するための方法
US20100190837A1 (en)	2007-02-15	2010-07-29	Isis Pharmaceuticals, Inc.	5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
EP2170917B1 (en)	2007-05-30	2012-06-27	Isis Pharmaceuticals, Inc.	N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en)	2007-06-08	2015-11-04	Isis Pharmaceuticals, Inc.	Carbocyclic bicyclic nucleic acid analogs
CA2692579C (en)	2007-07-05	2016-05-03	Isis Pharmaceuticals, Inc.	6-disubstituted bicyclic nucleic acid analogs
US8604192B2 (en)	2008-09-24	2013-12-10	Isis Pharmaceuticals, Inc.	Cyclohexenyl nucleic acids analogs
AT507215B1 (de)	2009-01-14	2010-03-15	Boehler Edelstahl Gmbh & Co Kg	Verschleissbeständiger werkstoff
EP2536738A4 (en) *	2010-02-08	2014-09-17	Isis Pharmaceuticals Inc	METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES OR SUFFERING IN CONNECTION WITH REPEAT EXTENSIONS
KR101869570B1 (ko)	2010-04-28	2018-06-20	아이오니스 파마수티컬즈, 인코포레이티드	변형된 뉴클레오사이드 및 그로부터 제조된 올리고머 화합물
JP5943993B2 (ja) *	2011-04-01	2016-07-05	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	転写のシグナル伝達及び活性化因子３（ｓｔａｔ３）発現の調節
JP2016528873A (ja) *	2012-05-16	2016-09-23	ラナセラピューティクスインコーポレイテッド	遺伝子発現を調節するための組成物及び方法
EA201492119A1 (ru) *	2012-05-16	2015-05-29	Рана Терапьютикс, Инк.	Композиции и способы для модулирования экспрессии apoa1 и abca1
US9984408B1 (en)	2012-05-30	2018-05-29	Amazon Technologies, Inc.	Method, medium, and system for live video cooperative shopping
US9778708B1 (en)	2016-07-18	2017-10-03	Lenovo Enterprise Solutions (Singapore) Pte. Ltd.	Dual sided latching retainer for computer modules

2014
- 2014-07-01 EP EP14819490.5A patent/EP3017044B1/en active Active
- 2014-07-01 RU RU2016102833A patent/RU2700244C2/ru active
- 2014-07-01 AU AU2014284398A patent/AU2014284398B2/en not_active Ceased
- 2014-07-01 CN CN201480038401.4A patent/CN105452461B/zh active Active
- 2014-07-01 KR KR1020167001790A patent/KR102236784B1/ko not_active Expired - Fee Related
- 2014-07-01 MX MX2015017863A patent/MX375446B/es active IP Right Grant
- 2014-07-01 ES ES14819490T patent/ES2787600T3/es active Active
- 2014-07-01 CA CA2917229A patent/CA2917229A1/en active Pending
- 2014-07-01 WO PCT/US2014/045088 patent/WO2015002971A2/en not_active Ceased
- 2014-07-01 EP EP20159386.0A patent/EP3730614A3/en not_active Withdrawn
- 2014-07-01 JP JP2016524320A patent/JP6487913B2/ja not_active Expired - Fee Related
- 2014-07-01 BR BR112015033069A patent/BR112015033069A2/pt not_active Application Discontinuation
- 2014-07-01 US US14/902,446 patent/US20170073689A1/en not_active Abandoned
2015
- 2015-12-14 IL IL243093A patent/IL243093B/en active IP Right Grant
2018
- 2018-12-27 US US16/234,409 patent/US20190225970A1/en not_active Abandoned
2019
- 2019-02-22 JP JP2019030128A patent/JP2019088329A/ja active Pending
2020
- 2020-01-28 AU AU2020200570A patent/AU2020200570A1/en not_active Abandoned
- 2020-02-20 IL IL272828A patent/IL272828A/en unknown
- 2020-05-27 US US16/884,782 patent/US20210108211A1/en not_active Abandoned
2022
- 2022-05-19 US US17/748,961 patent/US20230147811A1/en active Pending

Publication	Publication Date	Title
JP2019088329A5 (2)	2019-08-29
JP2018199700A5 (2)	2019-02-07
JP2021074021A5 (2)	2021-07-26
RU2016102833A (ru)	2017-08-07	Модуляторы рецептора гормона роста
JP2020022483A5 (2)	2020-05-14
RU2016146819A (ru)	2018-06-01	Композиции и способы модулирования экспрессии рецептора гормона роста
JP2012505660A5 (2)	2012-11-29
JP2018126141A5 (2)	2019-03-22
JP2016523548A5 (2)	2017-08-10
JP2014511686A5 (2)	2015-04-09
JP2009508527A5 (2)	2009-11-05
JP2017513469A5 (2)	2018-06-14
JP2016116520A5 (2)	2016-08-12
JP2012050438A5 (2)	2013-01-31
JP2016530882A5 (2)	2017-09-21
JP2021512629A5 (2)	2022-02-15
JP2018530560A5 (2)	2019-10-17
JP2014530004A5 (2)	2015-02-05
RU2011119479A (ru)	2012-11-27	Модуляция экспрессии фактора 11
RU2010116994A (ru)	2013-01-20	Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4)
RU2012114198A (ru)	2013-10-20	Модуляция экспрессии гентингтина
IL300119A (en)	2023-03-01	Oligonucleotides to induce paternal UBE3A expression
JP2010539950A5 (2)	2011-11-24
JP2017505116A5 (2)	2018-02-08
JP2022501024A5 (2)	2022-03-31